Medicare Drug Pricing Plan Survives Novartis' 3rd Circ. Appeal
By P.J. D'Annunzio · September 11, 2025, 10:11 PM EDT
The Third Circuit ruled Thursday that the Centers for Medicare & Medicaid Services' ability to negotiate "maximum fair prices" with drugmakers doesn't violate their constitutional rights, rejecting an argument by Novartis...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login